82294-70-0Relevant articles and documents
Synthesis method of 4-methylthiazole-5-formaldehyde
-
Paragraph 0028; 0031; 0034-0036; 0039-0041; 0044-0045, (2021/05/01)
The invention provides a synthesis method of 4-methylthiazole-5-formaldehyde. The method comprises the following steps: 1) dissolving 4-methylthiazole-5-ethanol in a solvent, and carrying out oxidation reaction in the presence of a catalyst to obtain 4-methylthiazole-5-acetic acid; and 2) carrying out heating reaction on the 4-methylthiazole-5-acetic acid obtained in the step 1) in the presence of oxygen and a metal salt catalyst to obtain the 4-methylthiazole-5-formaldehyde. According to the method, 4-methylthiazole-5-ethanol is used as a raw material, the raw material is green, cheap and easy to obtain, the reaction process is mild in condition and environmentally friendly, the result selectivity is good, the yield is high, good economic benefits are achieved, and the method is suitable for industrial production.
Novel preparation method for 4-methylthiazole-5-carboxaldehyde
-
Paragraph 0040; 0045; 0046; 0047; 0048; 0049; 0050, (2019/01/14)
The invention discloses a novel preparation method of 4-methylthiazole-5-carboxaldehyde. The novel preparation method includes the steps of subjecting 2-amino-4-methylthiazole to amino methylation toobtain 2-methylamino-4-methylthiazole, subjecting the 2-methylamino-4-methylthiazole to Vilsmeier reaction to obtain 2-methylamino-4-methyl-5-thiazolecarboxaldehyde, and hydrogenating the 2-methylamino-4-methyl-5-thiazolecarboxaldehyde to remove methylamino to obtain the 4-methylthiazole-5-carboxaldehyde. The preparation method has the advantages of moderate reaction condition, high yield, less generated waste and suitability for mass industrial production.
PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE -ACTIVATED CALCIUM CHANNEL
-
, (2011/04/26)
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.